#Dermatology Devices Market Is Projected to Grow at A CAGR Of 7.0% Forecast To 2026 Dermatology devices market is a billion dollars market accounting for a substantial proportion of healthcare expenditure globally. In a new report titled “Dermatology Devices Market: Global Industry Analysis and Opportunity Assessment, 2016–2026” Future Market Insights offers a 10-year forecast for the global dermatology devices market and provides insights on the drivers, restraints, opportunities, and trends likely to govern the global dermatology devices market during the forecast period (2016 – 2026). According to Future Market Insights analysis, the global dermatology devices market is expected to reach US$ 2,708.4 Mn in terms of revenue by 2016 end, witnessing a year-over-year growth of 6.2%. Factors such as rising prevalence of skin problems including acne leading to scars, increasing obesity, and growing aesthetic awareness among people are likely to contribute to the revenue growth of the global dermatology devices market over the forecast period. Economic factors such as growing healthcare expenditure, increasing disposable income per capita, and rising government support in developed economies are expected to boost the growth of the global dermatology devices market over the forecast period. Segmentation highlights The global dermatology devices market is segmented on the basis of Product Type (Lasers, RF Devices, Microdermabrasion Devices, Others); Application (Vascular Lesions, Tattoo Removal, Hair Removal, Wrinkle Removal, Scar Removal, Acne Removal, Others); and End User (Hospitals, Specialty Dermatology Clinics, Private Clinics). • The Lasers product type segment is projected to dominate the global dermatology devices market in terms of value over the forecast period. This segment is anticipated to hold a market value share of 46.5% by the end of 2016 • The RF Devices product type segment is expected to be the second most lucrative segment in the global dermatology devices market • The Vascular Lesions application segment is expected to account for 18.2% revenue share of the global dermatology devices market by 2016 end • The Hair Removal application segment is expected to reach US$ 915.6 Mn by 2026 owing to increase in prevalence of polycystic ovarian syndrome in women

#3D Printed Medical Devices Market Is Set to Expand at A CAGR Of 16.1% To Reach Us$ 1,839.2 Million During the Forecast Period 2022-2028 Currently heading towards a market value of over US$ 440 Mn, the global market for 3D printed medical devices is projected for stupendous growth at 16% CAGR during 2022- 2029. North America will remain the leading market for 3D printed medical device sales, whereas the market attractiveness of Asia Pacific has been rising notably. The market growth is primarily assisted by advancements in 3D printing technology, surging government spending in healthcare sector, increasing usage of 3D printed medical devices for medical procedures, and relative simplification of the manufacturing process of 3D printed medical devices. Introduction of Computer-aided Design (CAD) for 3D printing can create trail ready devices, thereby reducing manufacturing time, time to market as well as operational cost. Key Takeaways – 3D Printed Medical Devices Market Study • Although metals and alloys are most preferably used for 3D printed medical devices, biomaterial inks are expected to gain traction during the forecast period owing to their highly biocompatible and versatile physical properties. • PolyJet – InkJet 3D printing technology currently holds maximum share of 3D printed medical devices market. However, consistent development and adoption of innovative technologies may reduce the 3D printed medical devices market share of this technology during the forecast period. • Use of 3D printing technology in orthopedic implants is shaping the future of 3D printed medical devices market. It currently accounts for nearly half of the market value. • The consistently expanding patient pool and growing preference for personalized implants in joint replacement surgeries will remain key boosters to growth of 3D printed medical devices demand in orthopedics.

#Breast Pumps Market Is Set to Experience a Significant Growth Of 4.6% CAGR From 2022 To 2027 FMI, an ESOMAR-certified market research firm, states that the global breast pump market valuation of US$ 1.71 Bn in 2022. During the forecast period (2022-2027), the market is likely to grow at a CAGR of 4.6%. The world of infant feeding has been witnessing a “quiet revolution” since 2005. The usage of electric pumps has increased manifold since then. Initially it was confined only to mothers of premature babies in the NICU, but the current scenario is such that even full-term infants are being fed through pumped milk. A list of Key Players Covered in the Breast Pumps Market Are: • Koninklijke Philips N.V. • Pigeon Corporation • Newell Brands • Medela LLC • Ardo Medical AG

#Regenerative Medicine Market Current Scenario Trends, Comprehensive Analysis and Regional Forecast to 2026 The global regenerative medicine (bone and joint) market was valued at US$ 4,254.0 Mn in 2016, and is expected to grow at a year-over-year rate of 13.0% to reach US$ 4,808.9 Mn in 2016. In 2016, North America accounted for the largest revenue share of global regenerative medicine (bone & joints) market, representing a market value of US$ 2,039.8 Mn. Owing to increasing demand for bone and joint reconstructive surgeries and encouraging government initiatives, North America is expected to remain the largest market for regenerative medicine (bone and joint) in 2016. Europe is the second largest market for regenerative medicine, with the region’s high geriatric population fuelling adoption at a robust pace. By technology, biomaterials segment accounts for the highest market share globally, owing to favourable reimbursement policies and strong demand for biomaterials. Apart from biomaterials, tissue engineering is the other segment which is quickly gaining traction among end-users, and is projected to witness the highest year-over-year growth among all the technology segments. On the basis of application, bone graft substitute holds the highest share of the market in terms of value owing to a robust demand of bone graft substitute in orthopaedic treatments. However, complications associated with bone graft substitute can pose challenges to adoption in 2016 and beyond. While North America and Europe are key to the growth of the regenerative medicine market, rising awareness among healthcare professionals and patients in developing countries of Asia Pacific is expected to open up new opportunities for stakeholders. Favourable government initiatives in growing Asian economies such as China and India has paved the way for regenerative medicine market in the region. Moreover, adoption in developed countries of APAC, such as Japan and South Korea is also fuelling the growth of the market. Key participants in the global regenerative medicine market are: Medtronic, Inc. (INFUSE Bone Graft), DePuy Synthes, Inc. (HEALOS Bone Graft), Orthofix, Inc. (Trinity Evolution), NuVasive, Inc. (Osteocel Plus) and Zimmer Holdings, Inc. (CopiOs Bone Void Filler). The key strategy of these players is to expand globally through distribution agreements, mergers and acquisitions, public-private partnerships and new product development. To remain ‘ahead’ of your competitors, request a report sample @

Reduced overall time to market investment in new drugs, access to expensive technologies, and greater flexibility are some advantages offered by biopharmaceutical manufacturing companies. On the back of these factors, several large companies have outsourced their biopharmaceutical manufacturing operations. Biopharmaceutical contract manufacturing is highly preferred among biopharmaceutical companies with limited in-house production capacity. Pharmaceutical companies mainly focus on core areas of competence, and hence, do not prefer to take financial risks in the event of formulating the final dose of medicines. This is anticipated to accelerate the growth of the global biopharmaceutical contract manufacturing market during forecast period, estimated to be valued at US$ 18.7 Bn by 2029. Key Takeaways of Biopharmaceutical Contract Manufacturing Market Study • Although microbial-based platforms are abundantly used for the production of pharmaceuticals, mammalian-based cell culture is expected to gain traction during the forecast period, owing to higher efficiency and increasing demand. • In terms of product type, monoclonal antibodies currently hold a larger share of the biopharmaceutical contract manufacturing market, due to their superior efficacy as well as increasing adoption for the treatment of chronic diseases. • North America is anticipated to be the most lucrative region in the global biopharmaceutical contract manufacturing market, offering growth opportunities to market players. • The commercial application of biopharmaceutical contract manufacturing is expected to contribute a higher share as compared to clinical application by the end of 2029. List of Key Players Covered in Biopharmaceutical Contract Manufacturing market are: • Catalent Inc.

#Cellulite Treatment Market Is Projected to Grow at A Robust CAGR Of 7.8% Between 2022 And 2028 A new research report by Future Market Insights revolves around examining the current scenario of global cellulite treatment market as well as forecast for its upcoming years. This comprehensive research report is titled Cellulite Treatment Market: Global Industry Analysis 2013 – 2021 and Opportunity Assessment 2022 – 2028. The global Cellulite Treatment Market is set to enjoy a valuation of US$ 3.3 Bn in 2022, and is predicted to expand at an impressive CAGR of 7.8% to reach a valuation of US$ 5.2 Bn by 2028. Cellulite is a health condition which is more prevalent in women. With the growing health related complexities witnessed in women, there’s also a growth in rate of people suffering from cellulite. Hard Cellulite Predicted to Hold an Attractive Market Share in the Near Future One major driver behind the growth of cellulite treatment market is the increasing number of obese population. There are also increased number of cases for fat deposition. The people who are comparatively overweight mostly face this problem, in turn triggering the demand for cellulite treatment. These cases have helped people grow aware about cosmetic surgeries and has also broadened the scope of these surgeries in market. There’s a significant rise in aesthetic procedures taking place worldwide. Especially in Brazil, where there were around 5,500 cosmetic surgeons performing the second highest number of aesthetic procedures after the U.S. Around 1,450,020 minimally invasive and non-surgical procedures were performed in Brazil in 2016. Among different types of cellulite, hard cellulite is expected to register a growth rate of around 7.8% during 2022-2028, which is higher than other cellulite types. North America Slated for Strongest Projections in the Global Cellulite Treatment Market Among the major regional divisions made for the research conducted on global cellulite treatment market, North America shows the strongest prospects with an expected market value of over US$ 2,100 Mn by the end of 2028, growing at an impressive CAGR of 8.1% during the forecast period. The growth is helped by North America’s moderate economy and healthcare market.

#Eye Tracking System Market is expected to Witness Significant Growth of US$ 4.9 Billion by 2028 Eye Tracking System Market valuation of US$ 4.9 Bn by 2028, rapidly expanding at a CAGR of 26.6% from 2022 to 2028. Eye-tracking systems are therefore a key amalgamation of software and hardware which allows allowing retailers, automotive OEMs and researchers to assess and track the eye movements of the person to assess behaviour and movements. Consumer preference and safety are the two pivotal pillars guiding the retail and automobile industry. Critical information on the preference of consumer can be gathered through the way a viewer look at any website or a product and the duration of viewing a particular thing. Also with numerous fatalities associated with driver fatigue and drowsiness behind the wheel, it is important to adopt the precautionary measure. The Eye-tracking system allows for the measurement of the relative motion of the eye and most importantly the point of gaze of the person. Not limited to only retail and automotive applications, eye-tracking systems are also used for human-computer interaction, psycholinguistics, visual system, product design, marketing and psychology. Request a report sample to gain comprehensive insights @ https://www.futuremarketinsights.com/reports/sample/rep-gb-2010 The advance tracking system technology, leading car manufacturers are collaborating with eye-tracking system provider to incorporate safety measures and improve drivability. With opportunities, not only limited automobiles but the eye-tracking system technology is also being tested for aviation applications.

The In Vitro Diagnostics Market is indeed competitive, with numerous significant competitors. The industry is currently dominated by a few big companies in terms of market share. Mid-size to smaller businesses, on the other hand, are expanding their market presence by releasing new items at reduced prices, thanks to technical improvements and product innovations. In vitro diagnostic companies include Thermo Fischer Scientific Inc., Abbott Laboratories, Siemens Healthcare GmbH, and F. Hoffmann-La Roche AG. In addition, important players are active in strategic alliances with firms that complement their product lines, such as acquisitions, collaborations, and partnerships. F. Hoffmann-La Roche Ltd. and GenMark Diagnostics, Inc. announced their formal merger agreement in March 2021. Roche is likely to benefit from this purchase by gaining access to GenMark's innovative technology for testing a wide spectrum of infections with a single patient sample. Becton Dickinson and Company completed the acquisition of NAT Diagnostics in May 2020 to broaden its infectious disease point-of-care testing portfolio. F. Hoffmann-La Roche Ltd stated in March 2021 that Cobas pure integrated solutions would be available in countries that accept the CE certification. This innovative compact analyzer integrates three technologies on a single platform to assist small to medium-sized laboratories in streamlining operations. Siemens Healthineers AG, BD (Becton, Dickinson, and Company), Seegene Inc., DiaSorin S.p.A., and Quest Diagnostics Incorporated are among the other industry participants having a substantial presence in the worldwide market. To grow their market share, these businesses are anticipated to focus on launching new items. Key Takeaways